| Literature DB >> 26186195 |
Jung Hoon Woo1, Yishai Shimoni2, Wan Seok Yang3, Prem Subramaniam2, Archana Iyer2, Paola Nicoletti2, María Rodríguez Martínez2, Gonzalo López2, Michela Mattioli4, Ronald Realubit5, Charles Karan5, Brent R Stockwell6, Mukesh Bansal7, Andrea Califano8.
Abstract
Genome-wide identification of the mechanism of action (MoA) of small-molecule compounds characterizing their targets, effectors, and activity modulators represents a highly relevant yet elusive goal, with critical implications for assessment of compound efficacy and toxicity. Current approaches are labor intensive and mostly limited to elucidating high-affinity binding target proteins. We introduce a regulatory network-based approach that elucidates genome-wide MoA proteins based on the assessment of the global dysregulation of their molecular interactions following compound perturbation. Analysis of cellular perturbation profiles identified established MoA proteins for 70% of the tested compounds and elucidated novel proteins that were experimentally validated. Finally, unknown-MoA compound analysis revealed altretamine, an anticancer drug, as an inhibitor of glutathione peroxidase 4 lipid repair activity, which was experimentally confirmed, thus revealing unexpected similarity to the activity of sulfasalazine. This suggests that regulatory network analysis can provide valuable mechanistic insight into the elucidation of small-molecule MoA and compound similarity.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26186195 PMCID: PMC4506491 DOI: 10.1016/j.cell.2015.05.056
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 41.582